A Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANB020 in Healthy Subjects.

Trial Profile

A Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANB020 in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs ANB 020 (Primary) ; ANB 020 (Primary)
  • Indications Asthma; Atopic dermatitis; Peanut hypersensitivity
  • Focus Adverse reactions; First in man
  • Sponsors AnaptysBio
  • Most Recent Events

    • 06 Mar 2017 Results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 24 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 13 Feb 2017 According to an AnaptysBio media release, data from this trial will be presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting and the American Academy of Allergy, Asthma and Immunology (AAAAI) 2017 Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top